Jenny M Nguyen
Overview
Explore the profile of Jenny M Nguyen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
610
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schmitz K, Noonan K, Corman H, Nguyen J, Jimenez M, Reichman N
Am J Prev Med
. 2025 Feb;
PMID: 39894184
Introduction: The study investigated associations between paternal depression when children were age 5 and teacher-reported behavioral problems at age 9. Methods: 1,422 children in a U.S. cohort study of mostly...
2.
Stephen T, Payne K, Chaurio R, Allegrezza M, Zhu H, Perez-Sanz J, et al.
Immunity
. 2017 Jan;
46(1):51-64.
PMID: 28099864
Despite the importance of programmed cell death-1 (PD-1) in inhibiting T cell effector activity, the mechanisms regulating its expression remain poorly defined. We found that the chromatin organizer special AT-rich...
3.
Allegrezza M, Rutkowski M, Stephen T, Svoronos N, Perales-Puchalt A, Nguyen J, et al.
Cancer Res
. 2016 Nov;
76(21):6253-6265.
PMID: 27803104
Targeted therapies elicit seemingly paradoxical and poorly understood effects on tumor immunity. Here, we show that the MEK inhibitor trametinib abrogates cytokine-driven expansion of monocytic myeloid-derived suppressor cells (mMDSC) from...
4.
Svoronos N, Perales-Puchalt A, Allegrezza M, Rutkowski M, Payne K, Tesone A, et al.
Cancer Discov
. 2016 Oct;
7(1):72-85.
PMID: 27694385
Significance: Ablating estrogenic activity delays malignant progression independently of the tumor cell responsiveness, owing to a decrease in the mobilization and immunosuppressive activity of MDSCs, which boosts T-cell-dependent antitumor immunity....
5.
Perales-Puchalt A, Svoronos N, Rutkowski M, Allegrezza M, Tesone A, Payne K, et al.
Clin Cancer Res
. 2016 Jul;
23(2):441-453.
PMID: 27435394
Purpose: To define the safety and effectiveness of T cells redirected against follicle-stimulating hormone receptor (FSHR)-expressing ovarian cancer cells. Experimental Design: FSHR expression was determined by Western blotting, immunohistochemistry, and...
6.
Allegrezza M, Rutkowski M, Stephen T, Svoronos N, Tesone A, Perales-Puchalt A, et al.
Cancer Res
. 2016 Mar;
76(9):2561-72.
PMID: 26980764
Many signal transduction inhibitors are being developed for cancer therapy target pathways that are also important for the proper function of antitumor lymphocytes, possibly weakening their therapeutic effects. Here we...
7.
Tesone A, Rutkowski M, Brencicova E, Svoronos N, Perales-Puchalt A, Stephen T, et al.
Cell Rep
. 2016 Feb;
14(7):1774-1786.
PMID: 26876172
Special AT-rich sequence-binding protein 1 (Satb1) governs genome-wide transcriptional programs. Using a conditional knockout mouse, we find that Satb1 is required for normal differentiation of conventional dendritic cells (DCs). Furthermore,...
8.
Rutkowski M, Stephen T, Svoronos N, Allegrezza M, Tesone A, Perales-Puchalt A, et al.
Cancer Cell
. 2014 Dec;
27(1):27-40.
PMID: 25533336
The dominant TLR5(R392X) polymorphism abrogates flagellin responses in >7% of humans. We report that TLR5-dependent commensal bacteria drive malignant progression at extramucosal locations by increasing systemic IL-6, which drives mobilization...
9.
Stephen T, Rutkowski M, Allegrezza M, Perales-Puchalt A, Tesone A, Svoronos N, et al.
Immunity
. 2014 Sep;
41(3):427-439.
PMID: 25238097
Tumor-reactive T cells become unresponsive in advanced tumors. Here we have characterized a common mechanism of T cell unresponsiveness in cancer driven by the upregulation of the transcription factor Forkhead...